Histopathological and immunohistochemical findings on tissue microarrays, overall survival (OS), disease-free survival (DFS) and incidence of relapses (R) were recorded and statistically analyzed in 289 breast cancers. A higher R and a shorter DFS were significantly related to larger tumors, lymph node invasion, higher tumor grade, absence of estrogen receptors (ER), triple negative tumors, and presence of lymphovascular invasion (LVI). Longer OS was observed to be significantly associated with smaller tumor size (T), lymph node negativity, lower tumor grade, absence of LVI, lower Mib-1 expression and with the presence of ER. At multivariate analysis, only T for DFS and lymph node status and triple negativity either for DFS or OS had indepe...
Breast tumors exhibit extensive molecular and clinical heterogeneity. One of the most utilized breas...
Breast cancer (BC) exhibits great heterogeneity at histophatological, clinical and molecular levels....
Background: Serum tumor markers (STM) are still widely used in cancer patients, either in monitoring...
Histopathological and immunohistochemical findings on tissue microarrays, overall survival (OS), dis...
Aim: The new classification of breast cancer is based on microarray studies. Within the estrogen rec...
Commentary to:Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estr...
International audienceIntroduction: Breast cancers are traditionally divided into hormone-receptor p...
Breast cancer prognosis has improved greatly in recent years. Consequently, a thorough search for se...
BackgroundGene expression profiling of breast cancer has identified two biologically distinct estrog...
"Background Gene expression profiling of breast cancer has identified two biologically distinct estr...
The breast cancer survival in Sweden is good (almost 90 % 5-year relative survival) and has increase...
BACKGROUND: The group of estrogen receptor (ER)-positive breast cancers (both luminal-A and -B) beha...
Background: Cell proliferation has an important role as an indicator of biological aggressiveness in...
Breast cancer (BC) is a heterogeneous disease consisting of distinct subtypes that vary in prognosis...
The use of biomarkers ensures breast cancer patients receive optimal treatment. Established biomarke...
Breast tumors exhibit extensive molecular and clinical heterogeneity. One of the most utilized breas...
Breast cancer (BC) exhibits great heterogeneity at histophatological, clinical and molecular levels....
Background: Serum tumor markers (STM) are still widely used in cancer patients, either in monitoring...
Histopathological and immunohistochemical findings on tissue microarrays, overall survival (OS), dis...
Aim: The new classification of breast cancer is based on microarray studies. Within the estrogen rec...
Commentary to:Traditional and new prognosticators in breast cancer: Nottingham index, Mib-1 and estr...
International audienceIntroduction: Breast cancers are traditionally divided into hormone-receptor p...
Breast cancer prognosis has improved greatly in recent years. Consequently, a thorough search for se...
BackgroundGene expression profiling of breast cancer has identified two biologically distinct estrog...
"Background Gene expression profiling of breast cancer has identified two biologically distinct estr...
The breast cancer survival in Sweden is good (almost 90 % 5-year relative survival) and has increase...
BACKGROUND: The group of estrogen receptor (ER)-positive breast cancers (both luminal-A and -B) beha...
Background: Cell proliferation has an important role as an indicator of biological aggressiveness in...
Breast cancer (BC) is a heterogeneous disease consisting of distinct subtypes that vary in prognosis...
The use of biomarkers ensures breast cancer patients receive optimal treatment. Established biomarke...
Breast tumors exhibit extensive molecular and clinical heterogeneity. One of the most utilized breas...
Breast cancer (BC) exhibits great heterogeneity at histophatological, clinical and molecular levels....
Background: Serum tumor markers (STM) are still widely used in cancer patients, either in monitoring...